Mutational analysis of PINX1 in hereditary prostate cancer

Prostate

Volumn 60, Issue 4, 2004, Pages 298-302

  Hawkins, Gregory A ^a   Chang, Bao Li ^a   Zheng, S Lilly ^a   Isaacs, Sarah D ^b   Wiley, Kathleen E ^b   Bleecker, Eugene R ^a   Walsh, Patrick C ^b   Meyers, Deborah A ^a   Xu, Jianfeng ^a   Isaacs, William B ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

PinX1; Polymorphisms; Prostate cancer; Telomerase

Indexed keywords

ALANINE; ARGININE; CYSTEINE; GLUTAMINE; GLYCINE; HISTIDINE; ISOLEUCINE; LEUCINE; METHIONINE; SERINE; THREONINE;

ARTICLE; CANCER RISK; CANCER SCREENING; CHROMOSOME 8P; ENZYME REGULATION; GENE; GENE LOCATION; GENE MUTATION; GENETIC DISORDER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HETEROZYGOSITY LOSS; HUMAN; MALE; NUCLEOTIDE SEQUENCE; PINX1 GENE; PRIORITY JOURNAL; PROSTATE CANCER; STATISTICAL SIGNIFICANCE;

CHROMOSOMES, HUMAN, PAIR 8; DNA MUTATIONAL ANALYSIS; GENOTYPE; HUMANS; LOSS OF HETEROZYGOSITY; MALE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RISK FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 3943095351     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20075     Document Type: Article

References (31)

1. Zhou XZ, Lu KP. The Pin2/TRF1-interacting protein PinX1 is a potent telomerase inhibitor. Cell 2001;107:347-359.
2. Baffa R, Santoro R, Bullrich F, Mandes B, Ishii H, Croce CM. Definition and refinement of chromosome 8p regions of loss of heterozygosity in gastric cancer. Clin Cancer Res 2000;6:1372-1377.
3. Bova GS, Carter BS, Bussemakers MJ, Emi M, Fujiwara Y, Kyprianou N, Jacobs SC, Robinson JC, Epstein JI, Walsh PC, Isaacs WB. Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 1993;53:3869-3873.
4. Bova GS, MacGrogan D, Levy A, Pin SS, Bookstein R, Isaacs WB. Physical mapping of chromosome 8p22 markers and their homozygous deletion in a metastatic prostate cancer. Genomics 1996;35:46-54.
5. Kishimoto Y, Shiota G, Wada K, Kitano M, Nakamoto K, Kamisaki Y, et al. Frequent loss in chromosome 8p loci in liver cirrhosis accompanying hepatocellular carcinoma. J Cancer Res Clin Oncol 1996;122:585-589.
6. MacGrogan D, Levy A, Bova GS, Isaacs WB, Bookstein R. Structure and methylation-associated silencing of a gene within a homozygously deleted region of human chromosome band 8p22. Genomics 1996;35:55-65.
7. Liao C, Zhao M, Song H, Uchida K, Yokoyama KK, Li T. Identification of the gene for a novel liver-related putative tumor suppressor at a high-frequency loss of heterozygosity region of chromosome 8p23 in human hepatocellular carcinoma. Hepatology 2000;32:721-727.
8. Park WS, Lee JH, Park JY, Jeong SW, Shin MS, Kim HS, et al. Genetic analysis of the liver putative tumor suppressor (LPTS) gene in hepatocellular carcinomas. Cancer Lett 2002;178:199-207.
9. Liao C, Zhao MJ, Zhao J, Song H, Pineau P, Marchio A, et al. Mutation analysis of novel human liver-related putative tumor suppressor gene in hepatocellular carcinoma. World J Gastroenterol 2003;9:89-93.
10. Xu J, Zheng SL, Hawkins GA, Faith DA, Kelly B, Isaacs SD, et al. Linkage and association studies of prostate cancer susceptibility: Evidence for linkage at 8p22-23. Am J Hum Genet 2001;69:341-350.
11. Meeker AK, Hicks JL, Platz EA, March GE, Bennett CJ, Delannoy MJ, et al. Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. Cancer Res 2002;62:6405-6409.
12. Hawkins GA, Mychaleckyj JC, Zheng SL, Faith DA, Kelly B, Isaacs SD, et al. Germline sequence variants of the LZTS1 gene are associated with prostate cancer risk. Cancer Genet Cytogenet 2002;137:1-7.
13. Weir BS. Genetic data analysis II: Methods for discrete population genetic data. Sunderland, MA: Sinauer Associations, Inc. Publishers, 1996.
14. Zaykin D, Zhivotovsky L, Weir BS. Exact tests for association between alleles at arbitrary numbers of loci. Genetica 1995;96:169-178.
15. Laird NM, Horvath S, Xu X. Implementing a unified approach to family-based tests of association. Genet Epidemiol 2000;19 (Suppl 1):S36-S42.
16. Chang BL, Zheng SL, Hawkins GA, Isaacs SD, Wiley KE, Turner A, et al. Polymorphic GGC repeats in the androgen receptor gene are associated with hereditary and sporadic prostate cancer risk. Hum Genet 2002;110:122-129.
17. Hawkins GA, Cramer SD, Zheng SL, Isaacs SD, Wiley KE, Chang BL, et al. Sequence variants in the human 25-hydroxyvitamin D3 1-alpha-hydroxylase (CYP27B1) gene are not associated with prostate cancer risk. Prostate 2002;53:175-178.
18. Xu J, Zheng SL, Komiya A, Mychaleckyj JC, Isaacs SD, Hu JJ, et al. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 2002;32:321-325.
19. Chen C. Risk of prostate cancer in relation to polymorphisms of metabolic genes. Epidemiol Rev 2001;23:30-35.
20. Hsing AW. Hormones and prostate cancer: What's next? Epidemiol Rev 2001;23:42-58.
21. Miller GJ, Torkko KC. Natural history of prostate cancer-epidemiologic considerations. Epidemiol Rev 2001;23:14-18.
22. Dhaene K, Van Marck E, Parwaresch R. Telomeres, telomerase, and cancer: An up-date. Virchows Arch 2000;437:1-16.
23. Guo C, Geverd D, Liao R, Hamad N, Counter CM, Price DT. Inhibition of telomerase is related to the life span and tumorigenicity of human prostate cancer cells. J Urol 2001;166:694-698.
24. Kim Sh SH, Kaminker P, Campisi J. Telomeres, aging, and cancer: In search of a happy ending. Oncogene 2002;21:503-511.
25. Lin Y, Uemura H, Fujinami K, Hosaka M, Harada M, Kubota Y. Telomerase activity in primary prostate cancer. J.Urol 1997;157:1161-1165.
26. Uemura H, Kanda F, Ikeda N, Kubota Y. Telomerase activity in prostate cancer. Nippon Rinsho 2000;58Suppl:427-429.
27. Zhang W, Kapusta LR, Slingerland JM, Klotz LH. Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium. Cancer Res 1998;58:619-621.
28. Cunningham JM, Shan A, Wick MJ, McDonnell SK, Schaid DJ, Tester DJ, et al. Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. Cancer Res 1996;56:4475-4482.
29. Latil A, Lidereau R. Genetic aspects of prostate cancer. Virchows Arch 1998;432:389-406.
30. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-2015.
31. Shay JW, Bacchetti SA. Survey of telomerase activity in human cancer. Eur J Cancer 1997;33:787-791.